Mutual Advisors LLC Has $1.54 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Mutual Advisors LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,275 shares of the pharmaceutical company’s stock after buying an additional 191 shares during the quarter. Mutual Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,538,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in VRTX. Brighton Jones LLC boosted its holdings in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares during the period. GAMMA Investing LLC lifted its stake in Vertex Pharmaceuticals by 25.1% in the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock valued at $2,425,000 after acquiring an additional 1,005 shares during the last quarter. Johnson Investment Counsel Inc. lifted its stake in Vertex Pharmaceuticals by 0.5% in the first quarter. Johnson Investment Counsel Inc. now owns 7,919 shares of the pharmaceutical company’s stock valued at $3,839,000 after acquiring an additional 36 shares during the last quarter. Premier Path Wealth Partners LLC lifted its stake in Vertex Pharmaceuticals by 6.2% in the first quarter. Premier Path Wealth Partners LLC now owns 1,790 shares of the pharmaceutical company’s stock valued at $868,000 after acquiring an additional 104 shares during the last quarter. Finally, Compass Capital Corp MA ADV acquired a new stake in Vertex Pharmaceuticals in the first quarter valued at approximately $231,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $416.81 on Friday. The firm has a market capitalization of $106.87 billion, a PE ratio of 29.79 and a beta of 0.43. The company’s fifty day moving average price is $395.46 and its two-hundred day moving average price is $436.76. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the subject of a number of analyst reports. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 25th. Guggenheim dropped their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. UBS Group set a $553.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 5th. Truist Financial set a $490.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Morgan Stanley dropped their target price on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $494.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.